Slide 1: UCB ESG Roadshow
UCB ESG Roadshow November 2024
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor Forward-looking statements This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar exp
Slide 3: Agenda
01 Sustainability is an integrated part of UCB Proprietary and Confidential Property of UCB Agenda 02 Creating value for our key stakeholders in society 03 Summary of our performance 3
Slide 4: Sustainability is an integrated part of UCB
01 Sustainability is an integrated part of UCB Proprietary and Confidential Property of UCB 4
Slide 5: UCB key figures
UCB key figures* Our areas of focus Proprietary and Confidential Property of UCB >3.2 million 36 >9 000 patients treated presence in employees countries neurology 5.2 billion € 31% 25.7% immunology revenue R&D/revenue ratio adj. EBITDA/ revenue ratio *As of December 2023 More details in the 2023 UCB
Slide 6: We are defined by our purpose
We are defined by our purpose: Creating value for patients now and into the future. Proprietary and Confidential Property of UCB And sustainability is at our core, guided by our 2023 double materiality assessment. 6
Slide 7: On track to adapt UCB reporting to EU CSRD requirements
On track to adapt UCB performance reporting to EU CSRD* requirements Our 2023 updated materiality assessment Implementation of digital data management is guiding which CSRD standards are system to enable high-quality environmental, applicable to UCB for 2024 reporting social and governance data Prop
Slide 8: Sustainability is at the core of UCB
Sustainability is at the core of UCB Our focus on long term value creation is supported Sustainable value creation in Art. 3.1.1 of by Financiere de Tubize, our reference shareholder the UCB Corporate Governance Charter Proprietary and Confidential Property of UCB 8,5% Shareholder structure* Financi
Slide 9: UCB Board & Board Committees
UCB Board & Board Committees The Board is composed of 14 members (as follows since April 2024) : • 6 women (43%) • 10 independent directors (71%) • 8 countries • One executive board member (CEO) Proprietary and Confidential Property of UCB • Convincing mix of skills & experience including on sustain
Slide 10: Our governance supports our commitment to sustainable performance
Our governance supports our commitment to sustainable performance Maintain oversight of the organization’s strategy and sustainability matters, including sustainability-related risks, BOARD OF regularly reflect on specific environmental and DIRECTORS social topics material for UCB and approve extr
Slide 11: UCB External Sustainability Advisory Board
UCB External Sustainability Advisory Board Charlotte ERSBØLL Teresa FOGELBERG Bright SIMONS Founding partner at Hansen & Ersbøll Agenda Board Member of the Impact Economy Foundation Founder and President of mPedigree Proprietary and Confidential Property of UCB Chair of the UCB ESAB Background Backg
Slide 12: Our ethics in action
Our ethics in action 100% of UCB employees completed the Code of Conduct training in 2023* Proprietary and Confidential Property of UCB Yearly ethical culture survey has shown in 2023 that: • 93.6% of respondents agree they have a personal responsibility for making sure UCB behaves ethically • 91.9%
Slide 13: Driving Sustained Growth While Making a Positive Impact on Society
Driving Sustained Growth While Making a Positive Impact on Society (as of Dec 2023*) Value for patients >3.2 million patients treated 68% reimbursement coverage 32 launches 10 molecules in clinical development Proprietary and Confidential Property of UCB Value for people at UCB Preserved jobs while
Slide 14: Recognized for ESG Performance Across Key Rating Providers
We Are Recognized for Our ESG Performance Across Key Rating Providers ESG Rating Providers Index Memberships 2021 2022 2023 2024 Industry rank 2 / 404 of the 16.8 16.8 17.3 13.7 Proprietary and Confidential Property of UCB biotechnology subindustry Selected to be part of the new BEL ESG Index, with
Slide 15: Linking remuneration to sustainable performance
Linking remuneration to sustainable performance We aim to drive sustainable value creation while fostering a working environment where people can thrive. Proprietary and Confidential Property of UCB Our reward principles serve as a basis Stimulating sustained high performance for what UCB aims to in
Slide 16: Financial and extra-financial KPIs influence executive remuneration
Collective financial and extra-financial key performance indicators influence executive remuneration BONUS LTI – PERFORMANCE SHARES Proprietary and Confidential Property of UCB Individual Corporate Negative • 75%: performance performance modifier • Incentivize the achievement of 3-year revenue and c
Slide 17: Creating value for our key stakeholders in society
02 Creating value for our key stakeholders in society Proprietary and Confidential Property of UCB 17
Slide 18: Creating Value for Patients
Creating Value for Patients Proprietary and Confidential Property of UCB We innovate to bring differentiated solutions with unique outcomes that help diverse patients achieve their life goals. We are committed to improving access to these solutions for all patients who need them in a way which is vi
Slide 19: UCB's innovation delivering industry-leading pipeline
UCB’s innovation delivering industry-leading pipeline PHASE 1 PHASE 2 PHASE 3 TOPLINE RESULTS rozanolixizumab (FcRn inhibitor) MOG-antibody disease H2 2026 Severe fibromyalgia syndrome Ph-2a H2 2024 fenfluramine (5-HT agonist) CDKL5 deficiency disorder H2 2024 Proprietary and Confidential Property o
Slide 20: Increasing diversity in clinical trials
Working to ensure that participants in UCB clinical trials are reflective of the populations that will ultimately benefit from our new medicines Increasing diversity in clinical trials Key Programs • UCB Diversity Action Plan template based on the FDA draft Guidance of June 2024, and accompanying Gu
Slide 21: We put access to our solutions high on our agenda
We put access to our solutions high on our agenda OUR APPROACH • Integrating access from early development • Engaging with external stakeholders Our goal is that by 2030, all patients who Proprietary and Confidential Property of UCB • Conducting health equity research projects need our medicines in
Slide 22: Working in partnership with healthcare systems to ensure timely access
Working in partnership with healthcare systems to ensure timely access to patients who need our solutions in countries where we operate Access Performance Index 2023* How we calculate UCB Access Performance Index • Access Coverage Performance refers to the proportion of UCB products/indications that
Slide 23: Patient assistance programs and health equity research projects
Patient assistance programs and health equity research projects to address the needs of under-served populations in the US Identify, understand, and address health disparities to improve Patients benefitting from UCB patient experience and health outcomes assistance programs1 Opportunity: Where UCB
Slide 24: Our 1st social business in Mumbai, India
Our 1st social business in Mumbai, India for people with epilepsy The goal is to improve the situation of people Number of patients enrolled in UCB 1st social business as of with epilepsy on a sustainable basis* September 2024 Proprietary and Confidential Property of UCB Patients Enrolled 7000 6082
Slide 25: Creating value for our employees
Creating value for our employees Proprietary and Confidential Property of UCB At UCB, we value and nurture diverse perspectives and backgrounds and show respect and care for each other. We are made stronger because of our culture of innovation and collaboration which allows us to create value for pa
Slide 26: UCB employees see purpose in their work
UCB employees see purpose in their work Proprietary and Confidential Property of UCB Global Engagement Score is the average of responses to: 76% Purpose The work that I do at UCB is meaningful to me. 74/100 Retention I rarely think about looking for a job at a different company. Global Pride I feel
Slide 27: Prioritizing health, safety and wellbeing of our people
We continue to prioritize the health, safety and wellbeing of our people 2019 Launch Safety beyond 0 program (securing potential Life Changing Activities) 2020 • Delivery Model definition Proprietary and Confidential Property of UCB • First Health, Safety and Wellbeing Survey 2021 • > 95% of our emp
Slide 28: Measuring progress on health, safety and wellbeing
And we measure our progress on health, safety and wellbeing Health, Safety and Wellbeing Index 2023* Loss time Incident 100% SAFETY Rate (performance vs target) Proprietary and Confidential Property of UCB Annual Global Survey on current HSWB status 81.5% and areas for improvement 73.6% Employee met
Slide 29: On track to deliver on our DE&I aspirations
We are on track to deliver on our DE&I aspirations 2025 Aspirations Our progress towards 2025 8 Employee Resource Groups (ERGs) in 2023* Gender diversity 2023: 38%/62% Gender balance at executive level: 45/55 by 2025 Proprietary and Confidential Property of UCB MEMBERSHIP WORKFORCE Under-represented
Slide 30: Valuing the Planet
Valuing the Planet Proprietary and Confidential Property of UCB We take a long-term view of our business activities. We strive to uncouple our growth from our environmental footprint so that we can protect the planet for future generations. 30
Slide 31: Protecting human health means safeguarding the health of our planet
It is now clearer than ever that protecting human health also means safeguarding the health of our planet Proprietary and Confidential Property of UCB Source: World Health Organization. Link. 31
Slide 32: Clear targets for carbon neutral by 2030
We set clear targets* for becoming carbon neutral by 2030 and reducing our environmental impact Proprietary and Confidential Property of UCB Reduce by 38% the CO2e emissions Reduce water withdrawal by 20% by Reduce waste production by 25% by for the operations we control directly 2030. 2030. by 2030
Slide 33: Our path to decarbonization by 2030
Our path to decarbonization by 2030 compared to our 2015 baseline Scope 3 “goods and service Key initiatives across scope 1,2 and 3 suppliers”: % of suppliers (By CO2e emissions) committed to • Move to energy generated from renewable Sciences Based Targets alike* sources, purchased or produced on UC
Slide 34: Reducing water withdrawal by 20% by 2030
Reducing water withdrawal by 20% by 2030 compared to our 2015 baseline Water (m3)* Key programs 1.400.000 Proprietary and Confidential Property of UCB 1.200.000 Reducing • Replace existing equipment, processes and behaviors 1.000.000 with more ecofriendly equivalents 335.539 Forecasting “Do Nothing”
Slide 35: Green-by-design approach to minimize waste generation
We follow a green-by-design approach to minimize waste generation In 2023, we had a high level of construction Total waste (Tons) activity ongoing at our main manufacturing site 12.000 in Braine-l’Alleud which led to a significant 10.858 increase in our overall waste tonnage. Removing this construct
Slide 36: Creating value for our shareholders
Creating value for our shareholders Proprietary and Confidential Property of UCB We pay attention to patient insights and societal challenges to guide how we do business, create value and generate sustainable business growth. We aim to deliver long-term value to our shareholders, now and into the fu
Slide 37: 2023 Financial Performance Highlights
2023 Financial Performance Highlights Efficient performance and cost management 2023 Actual CER Net Sales € 4 867M (-5%; -6% CER) Revenue strong growth of BRIVIACT®, FINTEPLA® and BIMZELX®, more than offset by the loss of exclusivity of € 5 252 M -5% -6% 2 products, stable performance of CIMZIA® Wel
Slide 38: HY 2024 Financial Performance Highlights
HY 2024 Financial Performance Highlights Significant growth from new launches, substantial launch investments and strong EVENITY® contribution HY 2024 Actual CER Revenue Net Sales € 2 641 (+11%; +13% CER) driven by strong growth of BRIVIACT®, FINTEPLA®, BIMZELX® and RYSTIGGO® 2791 8% 10% Adjusted In
Slide 39: BIMZELX in U.S.: Strong Launch Execution
BIMZELX® in U.S.: Strong Launch Execution Delivering Competitive Uptake BIMZELX® | Uptake in PSO BIMZELX® | Access & Patient reach Psoriasis Launch Uptake vs. other anti-leukin antibodies1 High portion of paid prescriptions Week 34 included More than US holiday – 4th of July 5 000 patients Proprieta
Slide 40: BIMZELX Impactful Market Growth & Patient Reach
BIMZELX® Impactful Market Growth & Patient Reach with > 35 000 Patients Treated Worldwide BIMZELX® EU Market Share Evolution | PSO BIMZELX® in Germany | PsA & axSpA +85% patients in last 6 months Launch Uptake vs. other anti-interleukins2 40% Proprietary and Confidential Property of UCB 35% ~35% ~4%
Slide 41: Net Debt & Debt Maturity Schedule
Net Debt & Debt Maturity Schedule Net debt / adjusted EBITDA ratio Debt Maturity Schedule (as of 31 Dec 2023, € million) Proprietary and Confidential Property of UCB 1.000 2 100 2 000 2,00 750 1.6 1 600 1 441 1,50 1.6 500 1.0 1 100 1,00 860 € million 250 600 0,50 0.5 237 100 0.2 - 12 0,00 0 Cash 202
Slide 42: Strategically Investing Behind Launches and Securing Sustainable Growth
Strategically Investing Behind Launches and Securing Sustainable Growth Financial Guidance 2024 & 2025 confirmed 2024 Guidance 2025 Guidance Adjusted Revenue EBITDA / revenue At least Low- to mid-30s Improved expected margin expected Core EPS € 6 bn adj. EBITDA ESG rating Proprietary and Confidentia
Slide 43: Seize the opportunity provided by our unique position
Seize the opportunity provided by our unique position and fully expand the value of our growth drivers Proprietary and Confidential Property of UCB Propel our pipeline forward to deliver differentiated solutions Unlock resources to ensure our sustainable growth well into the future UCB - HY results
Slide 44: Summary of our performance
03 performance Summary of our 44 Proprietary and Confidential Property of UCB
Slide 45: 2023 UCB performance as reported in our integrated annual report
2023 UCB performance as reported in our integrated annual report Proprietary and Confidential Property of UCB 10 molecules in clinical Preserved jobs while € 5.2 bn revenues >160 global academic -55% CO2 emissions we development mitigating headwinds partnerships directly control vs. 2015 € 1.35 bn a
Slide 46: Thank you… Question time!
Proprietary and Confidential Property of UCB Thank you… Question time ! Proprietary and Confidential Property of UCB 46
Slide 47: The Roadshow Team
The Roadshow Team Veronique Toully (veronique.toully@ucb.com) Check out our IR App & • Head of Sustainability Proprietary and Confidential Property of UCB • Phone: +32 2 559 9229 stay tuned to UCB wherever you go! Xavier Michel (xavier.michel@ucb.com) • Head of Corporate Secretary Department • Phone
Slide 48: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB